Hiren R. Modi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hiren R. Modi has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
Surendra S. Katyare
The Maharaja Sayajirao University of Baroda
10 shared publicationsStanley I. Rapoport
Brain Physiology and Metabolism Section, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA
8 shared publicationsLisa Chang
Brain Physiology and Metabolism Section, National Institute on Aging, National Institutes of Health, 9000 Rockville Pike, Bldg. 9, 1S128, Bethesda, MD 20892, USA
4 shared publicationsMinal A. Patel
Department of Biochemistry, Faculty of Science, Maharaja Sayajirao University of Baroda, Vadodara, India
4 shared publicationsMireille Basselin
Brain Physiology and Metabolism Section Laboratory of Neurosciences National Institute on Aging National Institutes of Health Bethesda MD USA
4 shared publicationsSamir P. Patel
Department of Biochemistry, Faculty of Science, The Maharaja Sayajirao University of Baroda, Vadodara, Gujarat, India
4 shared publications
Latest Publications
- Open Access
- 14 September 2021
- Published by Wiley in Bioengineering & Translational Medicine
- Vol. 7 (1) , e10259
Systemic administration of dendrimer N‐acetyl cysteine improves outcomes and survival following cardiac arrest
Cardiac arrest (CA), the sudden cessation of effective cardiac pumping function, is still a major clinical problem with a high rate of early and long‐term mortality. Post‐cardiac arrest syndrome (PCAS) may be related to an early systemic inflammatory response leading to exaggerated and sustained neuroinflammation. Therefore, early intervention with targeted drug delivery to attenuate neuroinflammation may greatly improve therapeutic outcomes. Using a clinically relevant asphyxia CA model, we demonstrate that a single (i.p.) dose of dendrimer‐N‐acetylcysteine conjugate (D‐NAC), can target “activated” microglial cells following CA, leading to an improvement in post‐CA survival rate compared to saline (86% vs. 45%). D‐NAC treatment also significantly improved gross neurological score within 4 h of treatment (p < 0.05) and continued to show improvement at 48 h (p < 0.05). Specifically, there was a substantial impairment in motor responses after CA, which was subsequently improved with D‐NAC treatment (p < 0.05). D‐NAC also mitigated hippocampal cell density loss seen post‐CA in the CA1 and CA3 subregions (p < 0.001). These results demonstrate that early therapeutic intervention even with a single D‐NAC bolus results in a robust sustainable improvement in long‐term survival, short‐term motor deficits, and neurological recovery. Our current work lays the groundwork for a clinically relevant therapeutic approach to treating post‐CA syndrome.
- 14 September 2021
- Published by Wiley in Bioengineering & Translational Medicine
- Vol. 7 (1) , e10259
Open AccessSystemic administration of dendrimer N‐acetyl cysteine improves outcomes and survival following cardiac arrest
Cardiac arrest (CA), the sudden cessation of effective cardiac pumping function, is still a major clinical problem with a high rate of early and long‐term mortality. Post‐cardiac arrest syndrome (PCAS) may be related to an early systemic inflammatory response leading to exaggerated and sustained neuroinflammation. Therefore, early intervention with targeted drug delivery to attenuate neuroinflammation may greatly improve therapeutic outcomes. Using a clinically relevant asphyxia CA model, we demonstrate that a single (i.p.) dose of dendrimer‐N‐acetylcysteine conjugate (D‐NAC), can target “activated” microglial cells following CA, leading to an improvement in post‐CA survival rate compared to saline (86% vs. 45%). D‐NAC treatment also significantly improved gross neurological score within 4 h of treatment (p < 0.05) and continued to show improvement at 48 h (p < 0.05). Specifically, there was a substantial impairment in motor responses after CA, which was subsequently improved with D‐NAC treatment (p < 0.05). D‐NAC also mitigated hippocampal cell density loss seen post‐CA in the CA1 and CA3 subregions (p < 0.001). These results demonstrate that early therapeutic intervention even with a single D‐NAC bolus results in a robust sustainable improvement in long‐term survival, short‐term motor deficits, and neurological recovery. Our current work lays the groundwork for a clinically relevant therapeutic approach to treating post‐CA syndrome.
- Open Access
- 28 September 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (9) , e0182707
Intranasal post-cardiac arrest treatment with orexin-A facilitates arousal from coma and ameliorates neuroinflammation
Cardiac arrest (CA) entails significant risks of coma resulting in poor neurological and behavioral outcomes after resuscitation. Significant subsequent morbidity and mortality in post-CA patients are largely due to the cerebral and cardiac dysfunction that accompanies prolonged whole-body ischemia post-CA syndrome (PCAS). PCAS results in strong inflammatory responses including neuroinflammation response leading to poor outcome. Currently, there are no proven neuroprotective therapies to improve post-CA outcomes apart from therapeutic hypothermia. Furthermore, there are no acceptable approaches to promote cortical or cognitive arousal following successful return of spontaneous circulation (ROSC). Hypothalamic orexinergic pathway is responsible for arousal and it is negatively affected by neuroinflammation. However, whether activation of the orexinergic pathway can curtail neuroinflammation is unknown. We hypothesize that targeting the orexinergic pathway via intranasal orexin-A (ORXA) treatment will enhance arousal from coma and decrease the production of proinflammatory cytokines resulting in improved functional outcome after resuscitation. We used a highly validated CA rat model to determine the effects of intranasal ORXA treatment 30-minute post resuscitation. At 4hrs post-CA, the mRNA levels of proinflammatory markers (IL1β, iNOS, TNF-α, GFAP, CD11b) and orexin receptors (ORX1R and ORX2R) were examined in different brain regions. CA dramatically increased proinflammatory markers in all brain regions particularly in the prefrontal cortex, hippocampus and hypothalamus. Post-CA intranasal ORXA treatment significantly ameliorated the CA-induced neuroinflammatory markers in the hypothalamus. ORXA administration increased production of orexin receptors (ORX1R and ORX2R) particularly in hypothalamus. In addition, ORXA also resulted in early arousal as measured by quantitative electroencephalogram (EEG) markers, and recovery of the associated behavioral neurologic deficit scale score (NDS). Our results indicate that intranasal delivery of ORXA post-CA has an anti-inflammatory effect and accelerates cortical EEG and behavioral recovery. Beneficial outcomes from intranasal ORXA treatment lay the groundwork for therapeutic clinical approach to treating post-CA coma.
- 28 September 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (9) , e0182707
Open AccessIntranasal post-cardiac arrest treatment with orexin-A facilitates arousal from coma and ameliorates neuroinflammation
Cardiac arrest (CA) entails significant risks of coma resulting in poor neurological and behavioral outcomes after resuscitation. Significant subsequent morbidity and mortality in post-CA patients are largely due to the cerebral and cardiac dysfunction that accompanies prolonged whole-body ischemia post-CA syndrome (PCAS). PCAS results in strong inflammatory responses including neuroinflammation response leading to poor outcome. Currently, there are no proven neuroprotective therapies to improve post-CA outcomes apart from therapeutic hypothermia. Furthermore, there are no acceptable approaches to promote cortical or cognitive arousal following successful return of spontaneous circulation (ROSC). Hypothalamic orexinergic pathway is responsible for arousal and it is negatively affected by neuroinflammation. However, whether activation of the orexinergic pathway can curtail neuroinflammation is unknown. We hypothesize that targeting the orexinergic pathway via intranasal orexin-A (ORXA) treatment will enhance arousal from coma and decrease the production of proinflammatory cytokines resulting in improved functional outcome after resuscitation. We used a highly validated CA rat model to determine the effects of intranasal ORXA treatment 30-minute post resuscitation. At 4hrs post-CA, the mRNA levels of proinflammatory markers (IL1β, iNOS, TNF-α, GFAP, CD11b) and orexin receptors (ORX1R and ORX2R) were examined in different brain regions. CA dramatically increased proinflammatory markers in all brain regions particularly in the prefrontal cortex, hippocampus and hypothalamus. Post-CA intranasal ORXA treatment significantly ameliorated the CA-induced neuroinflammatory markers in the hypothalamus. ORXA administration increased production of orexin receptors (ORX1R and ORX2R) particularly in hypothalamus. In addition, ORXA also resulted in early arousal as measured by quantitative electroencephalogram (EEG) markers, and recovery of the associated behavioral neurologic deficit scale score (NDS). Our results indicate that intranasal delivery of ORXA post-CA has an anti-inflammatory effect and accelerates cortical EEG and behavioral recovery. Beneficial outcomes from intranasal ORXA treatment lay the groundwork for therapeutic clinical approach to treating post-CA coma.
- 26 April 2017
- Published by Elsevier in Psychiatry Research
- Vol. 254, 279-283
Valnoctamide, which reduces rat brain arachidonic acid turnover, is a potential non-teratogenic valproate substitute to treat bipolar disorder
- 26 April 2017
- Published by Elsevier in Psychiatry Research
- Vol. 254, 279-283
Valnoctamide, which reduces rat brain arachidonic acid turnover, is a potential non-teratogenic valproate substitute to treat bipolar disorder
- Open Access
- 20 October 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (10) , e110972
Coordinated Gene Expression of Neuroinflammatory and Cell Signaling Markers in Dorsolateral Prefrontal Cortex during Human Brain Development and Aging
Age changes in expression of inflammatory, synaptic, and neurotrophic genes are not well characterized during human brain development and senescence. Knowing these changes may elucidate structural, metabolic, and functional brain processes over the lifespan, as well vulnerability to neurodevelopmental or neurodegenerative diseases. Expression levels of inflammatory, synaptic, and neurotrophic genes in the human brain are coordinated over the lifespan and underlie changes in phenotypic networks or cascades. We used a large-scale microarray dataset from human prefrontal cortex, BrainCloud, to quantify age changes over the lifespan, divided into Development (0 to 21 years, 87 brains) and Aging (22 to 78 years, 144 brains) intervals, in transcription levels of 39 genes. Gene expression levels followed different trajectories over the lifespan. Many changes were intercorrelated within three similar groups or clusters of genes during both Development and Aging, despite different roles of the gene products in the two intervals. During Development, changes were related to reported neuronal loss, dendritic growth and pruning, and microglial events; TLR4, IL1R1, NFKB1, MOBP, PLA2G4A, and PTGS2 expression increased in the first years of life, while expression of synaptic genes GAP43 and DBN1 decreased, before reaching plateaus. During Aging, expression was upregulated for potentially pro-inflammatory genes such as NFKB1, TRAF6, TLR4, IL1R1, TSPO, and GFAP, but downregulated for neurotrophic and synaptic integrity genes such as BDNF, NGF, PDGFA, SYN, and DBN1. Coordinated changes in gene transcription cascades underlie changes in synaptic, neurotrophic, and inflammatory phenotypic networks during brain Development and Aging. Early postnatal expression changes relate to neuronal, glial, and myelin growth and synaptic pruning events, while late Aging is associated with pro-inflammatory and synaptic loss changes. Thus, comparable transcriptional regulatory networks that operate throughout the lifespan underlie different phenotypic processes during Aging compared to Development.
- 20 October 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (10) , e110972
Open AccessCoordinated Gene Expression of Neuroinflammatory and Cell Signaling Markers in Dorsolateral Prefrontal Cortex during Human Brain Development and Aging
Age changes in expression of inflammatory, synaptic, and neurotrophic genes are not well characterized during human brain development and senescence. Knowing these changes may elucidate structural, metabolic, and functional brain processes over the lifespan, as well vulnerability to neurodevelopmental or neurodegenerative diseases. Expression levels of inflammatory, synaptic, and neurotrophic genes in the human brain are coordinated over the lifespan and underlie changes in phenotypic networks or cascades. We used a large-scale microarray dataset from human prefrontal cortex, BrainCloud, to quantify age changes over the lifespan, divided into Development (0 to 21 years, 87 brains) and Aging (22 to 78 years, 144 brains) intervals, in transcription levels of 39 genes. Gene expression levels followed different trajectories over the lifespan. Many changes were intercorrelated within three similar groups or clusters of genes during both Development and Aging, despite different roles of the gene products in the two intervals. During Development, changes were related to reported neuronal loss, dendritic growth and pruning, and microglial events; TLR4, IL1R1, NFKB1, MOBP, PLA2G4A, and PTGS2 expression increased in the first years of life, while expression of synaptic genes GAP43 and DBN1 decreased, before reaching plateaus. During Aging, expression was upregulated for potentially pro-inflammatory genes such as NFKB1, TRAF6, TLR4, IL1R1, TSPO, and GFAP, but downregulated for neurotrophic and synaptic integrity genes such as BDNF, NGF, PDGFA, SYN, and DBN1. Coordinated changes in gene transcription cascades underlie changes in synaptic, neurotrophic, and inflammatory phenotypic networks during brain Development and Aging. Early postnatal expression changes relate to neuronal, glial, and myelin growth and synaptic pruning events, while late Aging is associated with pro-inflammatory and synaptic loss changes. Thus, comparable transcriptional regulatory networks that operate throughout the lifespan underlie different phenotypic processes during Aging compared to Development.
- 8 July 2014
- Published by Wiley in Bipolar Disorders
- Vol. 16 (8) , 875-880
Valnoctamide, a non‐teratogenic amide derivative of valproic acid, inhibits arachidonic acid activationin vitroby recombinant acyl‐CoA synthetase‐4
Objective: Valproic acid (VPA), a mood stabilizer used for treating bipolar disorder (BD), uncompetitively inhibits acylation of arachidonic acid (AA) by recombinant AA‐selective acyl‐CoA synthetase 4 (Acsl4) at an enzyme inhibition constant (Ki) of 25 mM. Inhibition may account for VPA's ability to reduce AA turnover in brain phospholipids of unanesthetized rats and to be therapeutic in BD. However, VPA is teratogenic. We tested whether valnoctamide (VCD), a non‐teratogenic amide derivative of a VPA chiral isomer, which had antimanic potency in a phase III BD trial, also inhibits recombinant Acsl4.Methods: Rat Acsl4‐flag protein was expressed inEscherichia coli. We used Michaelis–Menten kinetics to characterize and quantify the ability of VCD to inhibit conversion of AA to AA‐CoA by recombinant Acsl4in vitro.Results: Acsl4‐mediated activation of AA to AA‐CoA by Acsl4 was inhibited uncompetitively by VCD, with aKiof 6.38 mM.Conclusions: VCD's ability to uncompetitively inhibit AA activation to AA‐CoA by Acsl4, at a lowerKithan VPA, suggests that, like VPA, VCD may reduce AA turnover in rat brain phospholipids. If so, VCD and other non‐teratogenic Acsl4 inhibitors might be considered further for treating BD.
- 8 July 2014
- Published by Wiley in Bipolar Disorders
- Vol. 16 (8) , 875-880
Valnoctamide, a non‐teratogenic amide derivative of valproic acid, inhibits arachidonic acid activationin vitroby recombinant acyl‐CoA synthetase‐4
Objective: Valproic acid (VPA), a mood stabilizer used for treating bipolar disorder (BD), uncompetitively inhibits acylation of arachidonic acid (AA) by recombinant AA‐selective acyl‐CoA synthetase 4 (Acsl4) at an enzyme inhibition constant (Ki) of 25 mM. Inhibition may account for VPA's ability to reduce AA turnover in brain phospholipids of unanesthetized rats and to be therapeutic in BD. However, VPA is teratogenic. We tested whether valnoctamide (VCD), a non‐teratogenic amide derivative of a VPA chiral isomer, which had antimanic potency in a phase III BD trial, also inhibits recombinant Acsl4.Methods: Rat Acsl4‐flag protein was expressed inEscherichia coli. We used Michaelis–Menten kinetics to characterize and quantify the ability of VCD to inhibit conversion of AA to AA‐CoA by recombinant Acsl4in vitro.Results: Acsl4‐mediated activation of AA to AA‐CoA by Acsl4 was inhibited uncompetitively by VCD, with aKiof 6.38 mM.Conclusions: VCD's ability to uncompetitively inhibit AA activation to AA‐CoA by Acsl4, at a lowerKithan VPA, suggests that, like VPA, VCD may reduce AA turnover in rat brain phospholipids. If so, VCD and other non‐teratogenic Acsl4 inhibitors might be considered further for treating BD.
- 23 January 2013
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
- Vol. 1831 (4) , 880-886
Propylisopropylacetic acid (PIA), a constitutional isomer of valproic acid, uncompetitively inhibits arachidonic acid acylation by rat acyl-CoA synthetase 4: A potential drug for bipolar disorder
- 23 January 2013
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
- Vol. 1831 (4) , 880-886
Propylisopropylacetic acid (PIA), a constitutional isomer of valproic acid, uncompetitively inhibits arachidonic acid acylation by rat acyl-CoA synthetase 4: A potential drug for bipolar disorder
- RetractedOpen Access
- 22 January 2013
- Published by Wiley in Journal of Neurochemistry
- Vol. 125 (1) , 63-73
Retracted: Aging is associated with altered inflammatory, arachidonic acid cascade, and synaptic markers, influenced by epigenetic modifications, in the human frontal cortex
Aging is a risk factor for Alzheimer's disease (AD) and is associated with cognitive decline. However, underlying molecular mechanisms of brain aging are not clear. Recent studies suggest epigenetic influences on gene expression in AD, as DNA methylation levels influence protein and mRNA expression in postmortem AD brain. We hypothesized that some of these changes occur with normal aging. To test this hypothesis, we measured markers of the arachidonic acid (AA) cascade, neuroinflammation, pro‐ and anti‐apoptosis factors, and gene specific epigenetic modifications in postmortem frontal cortex from nine middle‐aged [41 ± 1 (SEM) years] and 10 aged subjects (70 ± 3 years). The aged compared with middle‐aged brain showed elevated levels of neuroinflammatory and AA cascade markers, altered pro and anti‐apoptosis factors and loss of synaptophysin. Some of these changes correlated with promoter hypermethylation of brain derived neurotrophic factor (BDNF), cyclic AMP responsive element binding protein (CREB), and synaptophysin and hypomethylation of BCL‐2 associated X protein (BAX). These molecular alterations in aging are different from or more subtle than changes associated with AD pathology. The degree to which they are related to changes in cognition or behavior during normal aging remains to be evaluated.
- 22 January 2013
- Published by Wiley in Journal of Neurochemistry
- Vol. 125 (1) , 63-73
RetractedOpen AccessRetracted: Aging is associated with altered inflammatory, arachidonic acid cascade, and synaptic markers, influenced by epigenetic modifications, in the human frontal cortex
Aging is a risk factor for Alzheimer's disease (AD) and is associated with cognitive decline. However, underlying molecular mechanisms of brain aging are not clear. Recent studies suggest epigenetic influences on gene expression in AD, as DNA methylation levels influence protein and mRNA expression in postmortem AD brain. We hypothesized that some of these changes occur with normal aging. To test this hypothesis, we measured markers of the arachidonic acid (AA) cascade, neuroinflammation, pro‐ and anti‐apoptosis factors, and gene specific epigenetic modifications in postmortem frontal cortex from nine middle‐aged [41 ± 1 (SEM) years] and 10 aged subjects (70 ± 3 years). The aged compared with middle‐aged brain showed elevated levels of neuroinflammatory and AA cascade markers, altered pro and anti‐apoptosis factors and loss of synaptophysin. Some of these changes correlated with promoter hypermethylation of brain derived neurotrophic factor (BDNF), cyclic AMP responsive element binding protein (CREB), and synaptophysin and hypomethylation of BCL‐2 associated X protein (BAX). These molecular alterations in aging are different from or more subtle than changes associated with AD pathology. The degree to which they are related to changes in cognition or behavior during normal aging remains to be evaluated.
- Open Access
- 1 November 2012
- Published by Wiley in Journal of Neurochemistry
- Vol. 124 (3) , 376-387
Chronic clozapine reduces rat brain arachidonic acid metabolism by reducing plasma arachidonic acid availability
Chronic administration of mood stabilizers to rats down‐regulates the brain arachidonic acid (AA) cascade. This down‐regulation may explain their efficacy against bipolar disorder (BD), in which brainAAcascade markers are elevated. The atypical antipsychotics, olanzapine (OLZ) and clozapine (CLZ), also act againstBD. When given to rats, both reduce brain cyclooxygenase activity and prostaglandin E2concentration;OLZalso reduces rat plasma unesterified and esterifiedAAconcentrations, andAAincorporation and turnover in brain phospholipid. To test whetherCLZproduces similar changes, we used ourin vivofatty acid method in rats given 10 mg/kg/day i.p.CLZ, or vehicle, for 30 days; or 1 day afterCLZwashout. [1‐14C]AAwas infused intravenously for 5 min, arterial plasma was collected and high‐energy microwaved brain was analyzed.CLZincreased incorporation coefficientsand ratesJin,iof plasma unesterifiedAAinto brain phospholipidsi, while decreasing plasma unesterified but not esterifiedAA. These effects disappeared after washout. Thus,CLZandOLZsimilarly down‐regulated kinetics and cyclooxygenase expression of the brainAAcascade, likely by reducing plasma unesterifiedAAavailability. Atypical antipsychotics and mood stabilizers may be therapeutic inBDby down‐regulating, indirectly or directly respectively, the elevated brainAAcascade of that disease.
- 1 November 2012
- Published by Wiley in Journal of Neurochemistry
- Vol. 124 (3) , 376-387
Open AccessChronic clozapine reduces rat brain arachidonic acid metabolism by reducing plasma arachidonic acid availability
Chronic administration of mood stabilizers to rats down‐regulates the brain arachidonic acid (AA) cascade. This down‐regulation may explain their efficacy against bipolar disorder (BD), in which brainAAcascade markers are elevated. The atypical antipsychotics, olanzapine (OLZ) and clozapine (CLZ), also act againstBD. When given to rats, both reduce brain cyclooxygenase activity and prostaglandin E2concentration;OLZalso reduces rat plasma unesterified and esterifiedAAconcentrations, andAAincorporation and turnover in brain phospholipid. To test whetherCLZproduces similar changes, we used ourin vivofatty acid method in rats given 10 mg/kg/day i.p.CLZ, or vehicle, for 30 days; or 1 day afterCLZwashout. [1‐14C]AAwas infused intravenously for 5 min, arterial plasma was collected and high‐energy microwaved brain was analyzed.CLZincreased incorporation coefficientsand ratesJin,iof plasma unesterifiedAAinto brain phospholipidsi, while decreasing plasma unesterified but not esterifiedAA. These effects disappeared after washout. Thus,CLZandOLZsimilarly down‐regulated kinetics and cyclooxygenase expression of the brainAAcascade, likely by reducing plasma unesterifiedAAavailability. Atypical antipsychotics and mood stabilizers may be therapeutic inBDby down‐regulating, indirectly or directly respectively, the elevated brainAAcascade of that disease.
- 1 September 2012
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
- Vol. 1821 (9) , 1278-1286
Disturbed brain phospholipid and docosahexaenoic acid metabolism in calcium-independent phospholipase A2-VIA (iPLA2β)-knockout mice
- 1 September 2012
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
- Vol. 1821 (9) , 1278-1286
Disturbed brain phospholipid and docosahexaenoic acid metabolism in calcium-independent phospholipase A2-VIA (iPLA2β)-knockout mice
- 31 August 2012
- Published by Elsevier in Prostaglandins, Leukotrienes and Essential Fatty Acids
- Vol. 87 (4-5) , 91-101
Altered lipid concentrations of liver, heart and plasma but not brain in HIV-1 transgenic rats
- 31 August 2012
- Published by Elsevier in Prostaglandins, Leukotrienes and Essential Fatty Acids
- Vol. 87 (4-5) , 91-101
Altered lipid concentrations of liver, heart and plasma but not brain in HIV-1 transgenic rats